Veru Inc. Stock price

Equities

VERU

US92536C1036

Personal Products

Real-time Estimate Cboe BZX 09:44:59 2024-03-28 am EDT 5-day change 1st Jan Change
0.695 USD +7.49% Intraday chart for Veru Inc. +9.59% -10.19%
Sales 2024 * 13M Sales 2025 * 22.5M Capitalization 94.65M
Net income 2024 * -34M Net income 2025 * -55M EV / Sales 2024 * 7.28 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 4.21 x
P/E ratio 2024 *
-2.59 x
P/E ratio 2025 *
-1.9 x
Employees 189
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.87%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.02%
1 week+9.59%
Current month+6.86%
1 month+0.06%
3 months-8.49%
6 months-17.10%
Current year-10.19%
More quotes
1 week
0.55
Extreme 0.55
0.65
1 month
0.54
Extreme 0.54
0.72
Current year
0.36
Extreme 0.36
0.76
1 year
0.36
Extreme 0.36
1.52
3 years
0.36
Extreme 0.36
24.55
5 years
0.36
Extreme 0.36
24.57
10 years
0.36
Extreme 0.36
24.57
More quotes
Managers TitleAgeSince
Founder 65 70-12-31
Chief Executive Officer 63 16-10-30
Director of Finance/CFO 65 12-12-31
Members of the board TitleAgeSince
Chief Executive Officer 63 16-10-30
Director/Board Member 49 16-10-30
Director/Board Member 66 18-02-28
More insiders
Date Price Change Volume
24-03-28 0.7049 +9.02% 369 388
24-03-27 0.6466 +6.02% 3,216,443
24-03-26 0.6099 +0.11% 522,386
24-03-25 0.6092 +8.79% 578,807
24-03-22 0.56 -2.42% 434,211

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6466 USD
Average target price
4 USD
Spread / Average Target
+518.62%
Consensus
  1. Stock
  2. Equities
  3. Stock Veru Inc. - Nasdaq